Vaderis Therapeutics Secures $152 Million for HHT Clinical Trial
A $152 million Series B financing round will propel the global Phase 3 HEROIC study, testing engasertib as the first potential treatment for hereditary hemorrhagic telangiectasia. EQT Life Sciences contributed $17.5 million to the round, joining a syndicate led by Goldman Sachs Alternatives and TCGX to address this rare, life-threatening vascular condition.
Hereditary hemorrhagic telangiectasia affects approximately 1 in 3,800 people, causing severe, recurrent nosebleeds and chronic anemia. Despite the severity of the genetic disorder, no approved therapies currently exist. The new funding provides the capital runway necessary to navigate the regulatory approval process for engasertib, which has already demonstrated clinically significant improvements in proof-of-concept data published in The New England Journal of Medicine.
Christoph Broja, a partner at EQT Life Sciences, will join the Vaderis board as an observer to guide the development strategy. The financing round also included participation from Omega Funds, Perceptive Advisors, and Kalehua Capital, alongside existing investors Medicxi and Droia. According to Azmi Nabulsi, president and CEO of Vaderis, the initiation of the HEROIC trial signifies a turning point for patients who have historically lacked dedicated medical options for their condition.
Comments (0)
No comments yet. Be the first!